Molecular Partners

Molecular Partners ROCE

The Return on Capital Employed (ROCE) of Molecular Partners (MOLN.SW) as of Oct 30, 2026 is -69.01 %. In the previous year, Return on Capital Employed (ROCE) was -43.22 % — a change of 59.66% (lower).

ROCE

-69.01 %

YoY

59.66%

Last updated:

In 2025, Molecular Partners's return on capital employed (ROCE) was -69.01 %, a 59.66% increase from the -43.22 % ROCE in the previous year.

The Molecular Partners ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-40.79 CHF
Jan 1, 2019
-67.71 CHF
Jan 1, 2020
-54.40 CHF
Jan 1, 2021
-59.02 CHF
Jan 1, 2022
49.59 CHF
Jan 1, 2023
-34.64 CHF
Jan 1, 2024
-43.22 CHF
Jan 1, 2025
-69.01 CHF
The Molecular Partners ROCE history
YEARROCEYoY
-69.01 %+59.66%
-43.22 %+24.79%
-34.64 %-169.85%
49.59 %-184.01%
-59.02 %+8.50%
-54.40 %-19.67%
-67.71 %+65.99%
-40.79 %+84.25%
-22.14 %+54.29%
-14.35 %+882.01%
-1.46 %-217.87%
1.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Molecular Partners Stock analysis

What does Molecular Partners do? Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Molecular Partners's Return on Capital Employed (ROCE)

Molecular Partners's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Molecular Partners's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Molecular Partners's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Molecular Partners’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Molecular Partners stock

Return on Capital Employed (ROCE) of Molecular Partners is -69.01 % in 2025.

Return on Capital Employed (ROCE) of Molecular Partners changed from -43.22 % to -69.01 %, representing a 59.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Molecular Partners since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Molecular Partners with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Molecular Partners

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Molecular Partners